Loading...
Loading...
Compugen Ltd.
disclosed today positive experimental results for
CGEN-15052, a novel immune checkpoint candidate for cancer immunotherapy,
which in several experimental settings demonstrated robust inhibition of T
cell activation, both as a membrane protein and as an Fc fusion protein.
Initial testing of human cancer tissue samples with a polyclonal antibody
indicated that CGEN-15052 is expressed in multiple epithelial cancers, with
particularly high expression in lung cancer samples. These positive findings
support CGEN-15052's involvement in tumor immunology and its potential as a
target for cancer immunotherapy.
Compugen also disclosed today the predictive discovery of two new B7-like
immune checkpoint candidates, increasing to eleven the total number of such
candidates discovered to date by the Company in this area of high medical and
pharmaceutical industry interest. The predictive discovery of these two new
immune checkpoint candidates was accomplished utilizing the same predictive
models and algorithms that led to the identification of nine novel candidates
in the Company's earlier discovery efforts, but followed enhancement of these
models and algorithms through incorporation of additional information obtained
from those initial efforts.
Dr. Anat Cohen Dayag, Compugen's President and CEO, stated, “Our disclosures
today of successful experimental results for another of our initial nine
checkpoint discoveries, and of new discoveries from a follow-on run utilizing
the same predictive models, but enhanced with information from such initial
discovery efforts, provide excellent validation of the value and uniqueness of
our predictive discovery capabilities. After more than a decade of extensive
multidisciplinary research to gain deeper understanding of key biological
phenomena, providing the basis for the creation of our predictive models and
discovery platforms, it is very rewarding to see these promising results from
our first focused use of this powerful capability.”
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in